Selected article for: "control group and plasma treatment"
Author: Abolghasemi, Hassan; Eshghi, Peyman; Cheraghali, Abdol Majid; Imani Fooladi, Abbas Ali; Bolouki Moghaddam, Farzaneh; Imanizadeh, Sina; Moeini Maleki, Matin; Ranjkesh, Mohammad; Rezapour, Mohammad; Bahramifar, Ali; Einollahi, Behzad; Hosseini, Mohammad Javad; Jafari, Nematollah Joneidi; Nikpouraghdam, Mohamad; Sadri, Nariman; Tazik, Mokhtar; Sali, Shanaz; Okati, Shamsi; Askari, Elham; Tabarsi, Payam; Aslani, Jafar; Sharifipour, Ehsan; Jarahzadeh, Mohammad Hossein; Khodakarim, Nastaran; Salesi, Mahmood; Jafari, Ramezan; Shahverdi, Samira
Title: Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
  • Cord-id: oywmmcg7
  • Document date: 2020_7_15
    • ID: oywmmcg7
    Snippet: Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infec
    Document: Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and lobar involvement: 1, 2, 3
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung field: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission date and lopinavir ritonavir: 1, 2, 3
    • admission date and lung involvement: 1, 2
    • lobar involvement and lung involvement: 1, 2, 3, 4, 5, 6, 7
    • lobar score and lung involvement: 1, 2
    • lopinavir ritonavir and low number: 1
    • lopinavir ritonavir and lung field: 1
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5